Sensus Healthcare (NASDAQ:SRTS) Stock Rating Lowered by B. Riley

Share on StockTwits

Sensus Healthcare (NASDAQ:SRTS) was downgraded by research analysts at B. Riley from a “buy” rating to a “neutral” rating in a report released on Thursday, MarketBeat reports. They currently have a $5.50 price target on the stock, down from their previous price target of $14.00. B. Riley’s price objective would indicate a potential upside of 44.74% from the stock’s current price.

Several other analysts also recently weighed in on the stock. Maxim Group set a $11.00 target price on shares of Sensus Healthcare and gave the company a “buy” rating in a report on Friday, August 9th. ValuEngine downgraded shares of Sensus Healthcare from a “buy” rating to a “hold” rating in a report on Thursday, October 17th. TheStreet upgraded shares of Sensus Healthcare from a “d+” rating to a “c-” rating in a report on Monday, August 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sensus Healthcare in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.30.

Sensus Healthcare stock traded down $0.21 during midday trading on Thursday, reaching $3.80. The company had a trading volume of 73,900 shares, compared to its average volume of 31,014. The firm’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $5.72. The company has a market capitalization of $93.54 million, a P/E ratio of -27.14 and a beta of -0.41. Sensus Healthcare has a 12-month low of $3.71 and a 12-month high of $9.23.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $7.77 million. Sensus Healthcare had a negative net margin of 8.65% and a negative return on equity of 8.82%. On average, research analysts forecast that Sensus Healthcare will post -0.12 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Essex Investment Management Co. LLC acquired a new stake in Sensus Healthcare in the 3rd quarter valued at approximately $540,000. Susquehanna International Group LLP grew its stake in shares of Sensus Healthcare by 69.9% in the second quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after acquiring an additional 11,311 shares in the last quarter. BlackRock Inc. grew its stake in shares of Sensus Healthcare by 40.7% in the second quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after acquiring an additional 29,990 shares in the last quarter. Heartland Advisors Inc. grew its stake in shares of Sensus Healthcare by 150.0% in the second quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock worth $2,078,000 after acquiring an additional 225,000 shares in the last quarter. Finally, Wells Fargo & Company MN acquired a new position in shares of Sensus Healthcare in the second quarter worth $30,000. Hedge funds and other institutional investors own 9.95% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Article: Moving Average (MA)

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.